Literature DB >> 34491462

Cross-reactivity of Haemophilus influenzae type a and b polysaccharides: molecular modeling and conjugate immunogenicity studies.

Nicole I Richardson1, Michelle M Kuttel2, Frank St Michael3, Chantelle Cairns3, Andrew D Cox3, Neil Ravenscroft4.   

Abstract

Haemophilus influenzae is a leading cause of meningitis disease and mortality, particularly in young children. Since the introduction of a licensed conjugate vaccine (targeting the outer capsular polysaccharide) against the most prevalent serotype, Haemophilus influenzae serotype b, the epidemiology of the disease has changed and Haemophilus influenzae serotype a is on the rise, especially in Indigenous North American populations. Here we apply molecular modeling to explore the preferred conformations of the serotype a and b capsular polysaccharides as well as a modified hydrolysis resistant serotype b polysaccharide. Although both serotype b and the modified serotype b have similar random coil behavior, our simulations reveal some differences in the polysaccharide conformations and surfaces which may impact antibody cross-reactivity between these two antigens. Importantly, we find significant conformational differences between the serotype a and b polysaccharides, indicating a potential lack of cross-reactivity that is corroborated by immunological data showing little recognition or killing between heterologous serotypes. These findings support the current development of a serotype a conjugate vaccine.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Capsular polysaccharide; Conformation; Cross protection; Haemophilus influenzae type a; Immunogenicity; Molecular modeling

Mesh:

Substances:

Year:  2021        PMID: 34491462     DOI: 10.1007/s10719-021-10020-0

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  31 in total

1.  An NMR spectroscopic identity test for the control of the capsular polysaccharide from Haemophilus influenzae type b.

Authors:  X Lemercinier; C Jones
Journal:  Biologicals       Date:  2000-09       Impact factor: 1.856

2.  A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.

Authors:  V Verez-Bencomo; V Fernández-Santana; Eugenio Hardy; Maria E Toledo; Maria C Rodríguez; Lazaro Heynngnezz; Arlene Rodriguez; Alberto Baly; Luis Herrera; Mabel Izquierdo; Annette Villar; Yury Valdés; Karelia Cosme; Mercedes L Deler; Manuel Montane; Ernesto Garcia; Alexis Ramos; Aristides Aguilar; Ernesto Medina; Gilda Toraño; Iván Sosa; Ibis Hernandez; Raydel Martínez; Alexis Muzachio; Ania Carmenates; Lourdes Costa; Félix Cardoso; Concepción Campa; Manuel Diaz; René Roy
Journal:  Science       Date:  2004-07-23       Impact factor: 47.728

3.  Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need.

Authors:  Andrew D Cox; Dean Williams; Chantelle Cairns; Frank St Michael; Perry Fleming; Evgeny Vinogradov; Mélanie Arbour; Luke Masson; Wei Zou
Journal:  Vaccine       Date:  2017-09-23       Impact factor: 3.641

4.  Extracting general practice data for timely vaccine coverage estimates: The England experience.

Authors:  Michael Edelstein; Tim Crocker-Buque; Camille Tsang; Odette Eugenio; Tim Hopson; Richard Pebody; Mary Ramsay; Joanne M White
Journal:  Vaccine       Date:  2017-08-16       Impact factor: 3.641

5.  The molecular basis of pathogenicity in Haemophilus influenzae: comparative virulence of genetically-related capsular transformants and correlation with changes at the capsulation locus cap.

Authors:  A Zwahlen; J S Kroll; L G Rubin; E R Moxon
Journal:  Microb Pathog       Date:  1989-09       Impact factor: 3.738

Review 6.  Haemophilus influenzae serotype a as a cause of serious invasive infections.

Authors:  Marina Ulanova; Raymond S W Tsang
Journal:  Lancet Infect Dis       Date:  2013-11-20       Impact factor: 25.071

7.  Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'.

Authors:  Affan Shoukat; Robert Van Exan; Seyed M Moghadas
Journal:  Vaccine       Date:  2018-02-16       Impact factor: 3.641

Review 8.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

9.  Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.

Authors:  Julia H Rogers; Sarah N Cox; James P Hughes; Amy C Link; Eric J Chow; Idabelle Fosse; Margaret Lukoff; M Mia Shim; Timothy M Uyeki; Constance Ogokeh; Michael L Jackson; Michael Boeckh; Janet A Englund; Emily Mosites; Melissa A Rolfes; Helen Y Chu
Journal:  Vaccine       Date:  2021-11-15       Impact factor: 3.641

View more
  2 in total

1.  Comparative Molecular Modelling of Capsular Polysaccharide Conformations in Streptococcus suis Serotypes 1, 2, 1/2 and 14 Identifies Common Epitopes for Antibody Binding.

Authors:  Michelle M Kuttel
Journal:  Front Mol Biosci       Date:  2022-02-08

2.  Modeling of pneumococcal serogroup 10 capsular polysaccharide molecular conformations provides insight into epitopes and observed cross-reactivity.

Authors:  Nicole I Richardson; Michelle M Kuttel; Neil Ravenscroft
Journal:  Front Mol Biosci       Date:  2022-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.